Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the efficacy and safety of Salmeterol-Fluticasone
（ICS and LABA）combined inhaled therapy for non-cystic fibrosis（non-CF）bronchiectasis patients
with chronic airflow obstruction. Moreover, subgroup analysis is performed to explore which
populations of bronchiectasis patients this treatment is suitable for.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate